Dr. Advani Discusses Front-Line Brentuximab

Ranjana Advani, MD
Published: Monday, May 06, 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Brentuximab is currently approved for Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin will not be beneficial for all subtypes of lymphoma, Advani says, but will be for CD30-positive lymphomas. This is an exciting potential development because about 30% of other T-cell lymphomas also express CD30.

Advani looking forward to the large randomized trial evaluating CHOP chemotherapy plus placebo compared to CHOP plus brentuximab.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Brentuximab is currently approved for Hodgkin lymphoma and anaplastic large cell lymphoma. Brentuximab vedotin will not be beneficial for all subtypes of lymphoma, Advani says, but will be for CD30-positive lymphomas. This is an exciting potential development because about 30% of other T-cell lymphomas also express CD30.

Advani looking forward to the large randomized trial evaluating CHOP chemotherapy plus placebo compared to CHOP plus brentuximab.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x